A sensitive and accurate method for the spectrofluorimetric determination of trace levels of aluminum in hemodialysis solutions using Mordant Red 19 as the complexation reagent has been developed. The optimal experimental conditions for the concentration of fluorimetric reagent, pH, temperature, and the specific type of matrix are reported. The emission of the fluorescent metal chelate was measured at 555 nm, excitation at 478 nm. tinearity between emission intensity and aluminum concentration was found in the 2-20 ppb range in standard aluminum solutions. Limit of detection was 0.4 ppb. The aluminum amounts in some commercial hemodialysis solutions were determined by means of the extrapolation method. The proposed method proved to be suitable in terms of sensitivity and accuracy for the determination of aluminum in dialysis fluids.
Introduction
It is certain that aluminum (Al), which was once considered a nontoxic element, is responsible for severe illnesses (1-3), especially in patients suffering from chronic renal failure who need periodic and long-term hemodialysis treatments (4, 5) . Aluminum-dependent toxicity manifests itself with anemia, bone diseases, encephalopathies, and neurological illness. This last type of illness is called "dialysis dementia", a neurological syndrome that which starts as speech impairment and progresses with conclamate dementia and convulsions (1, 4) . It has indeed been confirmed that Al accumulates not only in the bone, but also in the brain. For this reason, Al has been recently associated with Alzheimer's disease, which manifests itself in the senile and presenile ages as central nervous system degeneration. One of the factors linking AI to the cascade of events leading to neuronal death and thus to the disease's onset is its binding to ferritin. Ferritin is a protein that can bind both iron and Al and, when it is extracted from the brains of individuals suffering from Alzheimer's disease, contains AI concentrations 5 or 6 times larger than those found in healthy individuals (6) .
The importance of monitoring trace A1 levels in dialysis solu-tions is apparent. To this end, bearing in mind that Al toxicity manifests even at very low doses of A1 (in the part-per-billion range) (7, 8) , highly sensitive and completely reliable analytical methods are needed in order to correctly estimate AI concentrations.
Several methods for the analysis of Al from different sources have been reported in literature, and they include the use of neutron activation (9), electrochemical procedures (10, 11) , and emission spectrometry (12) (13) (14) , but the most frequently used technique was atomic absorption spectrometry (14) (15) (16) (17) (18) (19) (20) . However, the high salt concentrations present in all dialysis solutions produce heavy interference in these determinations. In order to solve this difficult analytical challenge, we selected molecular spectrofluorimetry because of its high selectivity and sensitivity. Previous studies performed in our laboratory led to the development and application of fluorimetric methods for the determination of Al in hemodialysis solutions (21, 22) and in pharmaceutical formulations (23, 24) . These methods are based on the use of Morin and Pontachrome Blue-Black dyestuffs as complexing reagents. Now, a new spectrofluorimetric method based on the Mordant Red 19 (MR19) reagent has been developed and implemented by our group. MRI9 reacts with A1 to give rise to a very stable, intensely fluorescent complex with a characteristic emission spectrum.
This method allows for an accurate toxicological quality-control of dialysis solutions, in order to veri~ if Al levels are in the very low admissible range. This is the first step in a broader dinica] epidemiology study, which is planned to "follow up" on populations subjected to dialysis treatment to verify the neurotoxic effects of aluminum. This study will be further expanded by a pharmacological experimental investigation, in order to find prospective antidotes to aluminum. From recent literature (25) , silicon appears to be one of the candidates.
Experimental

Apparatus and chemicals
The pH values of all solutions were measured with a Crisen (Barcelona, Spain) model 501 primelet (pH + 0.01). Fluorescence intensities were measured with a Perkin Elmer (Beaconsfield, Buckinghamshire, England) LS-5 spectrofluorimeter.
Absorbance spectra were recorded using a Jasco (Tokyo, Japan) UVIDEC-610 double-beam spectrophotometer.
All reagents were analytical grade. Standard aluminum solutions (1 g/L) for atomic absorption, glacial acetic acid, sodium hydroxide, n-propylic alcohol, phenanthroline, 37% HCI, and acetone were purchased from Merck (Darmstadt, Germany); 5-chloro-3-[(4,5-dihydro-3-methyl-5-hydroxy-l-phenyl]-lHpyrazol-4-yl)azo]-2-hydroxy-benzensulfonic acid monosodic salt (Mordant Red 19) was purchased from Sigma Chemical (St. Louis, MO). All solutions were prepared using ultrapure water from a Millipore (Bedford, MA) MilliQ apparatus.
The hemodialysis solutions (SIF-BH 504/B, SIF-BH 499, SIF-BP 466/A) were from Sifra (Isola della Scala, Verona, Italy).
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Standard solutions
All solutions, except the MR19 stock solution, were prepared in low-release PMP volumetric flasks. MR19 stock solution (0.039mM). MR19 (5.12 rag) was dissolved in 200 mL of n-propylic alcohol. The solution was used after being stored for at least 24 h. pH 5.15 Buffer solution. One-hundred milliliters of a 1N NaOH solution and 138 mL of glacial acetic acid were brought up to 1 L volume with ultrapure water. The resulting buffer solution had pH 5.15 and ionic strength 0.1.
0.01MPhenanthroline solution. Phenanthroline (0.12 g) was dissolved in ultrapure water and brought up to 50 mL.
Aluminum stock solution (1 g/L)
. A vial containing the standard aluminum for atomic absorption was diluted with ultrapure water to 1 L.
Standard aluminum solution (101~g/mL). A 1-mL aliquot of A1 stock solution was diluted to 100 mL with pH 5.15 buffer solution.
Procedures
Calibration curve. In a PMP flask, 2.5 mL ofn-propylic alcohol, 2.5 mL of MR19 stock solution, 0.15 mL of phenanthroline solution, and 1 or 2 mL of ultrapure water were brought up to 12.5 mL volume with pH 5.15 buffer solution. Then, 0 to 100 IJL of standard aluminum solution (100 1Jg/mL) was added. The resulting solutions were heated at 70~ for 60 min. Emission intensity was measured at wavelength (~) 555 nm, and excitation was measured at ~, 478 nm. Emission intensities were plotted against Al concentration.
Sample assay. Flasks were prepared as described, except the hemodialysis solution sample was substituted for the ultrapure water, and they were subjected to the same treatment. Emission intensities were plotted against added Al concentration. The aluminum concentrations in the sample were determined by the extrapolation method.
Precision and recovery. In order to evaluate the intraday precision or repeatability of the method, seven samples of the same hemodialysis solution were prepared and treated as described, then subjected to analysis. Recovery assays were performed by spiking hemodialysis solution samples with known amounts of standard aluminum solution, then subjecting them to the usual analytical procedure.
Results and Discussion
The complexing agent MR19 (Figure 1 ) was selected after a careful examination of several dyestuffs in the Mordant series because it allowed for the highest sensitivity and stability of the aluminum complex (26) .
A fluorescence emission spectrum of a standard aluminum solution treated with MR19 is shown in Figure 2 . It can be seen that the emission maximum appears at 555 nm when excitation is at 478 rim.
Study of the optimal experimental conditions
ExperimentalpH. Because aluminum is an amphoteric metal, the search for the best reaction pH was limited to average pH values of 4. Reaction temperature. The temperature effect on the reaction rate was investigated. The reaction is complete after 180 rain at 50~ after 129 rain at 60~ and after 60 rain at 70~ as can be seen from Figure 3 .
This last condition was chosen for all experiments.
Method validation
Once the experimental parameters were optimised, the calibration curve, the method accuracy and precision and the limit of detection were determined. Linearity was found in the 2-20 ng/mL Al concentration range.
In order to evaluate the reproducibility of fluorescence intensity values and to test possible contamination in our experimental conditions, calibration curves were performed on different days
The results obtained on four different days are shown in Table I . As can be seen, the coefficients of the regression equations are very similar and the correlation coefficients are good. The linear regression calculated on all data was y= 4.87x + 5.75, where y represents the fluorescence emission intensity values (in arbitrary units), whereas x represents the AI concentration values (in nanograms per milliliter); R c = 0:998. Moreover, the amount of A1 in "blank" is very low (approximately 2 ng/mL). The quantitation limit (LOQ) was 0.6 ng/mL, whereas the detection limit (LOD) was 0.4 ng/mL.
The repeatability (or intraday precision) of this procedure is very good; the relative standard deviations (RSD%) of fluorescence intensity obtained were 2.45 and 1.46 for AI concentrations of 8 and 16 ng/mL, respectively (n = 7).
Application to hemodialysis solutions
Having so validated the method, it was applied to the assay of AI levels in some commercially available hemofiltration solutions, whose composition is reported in Table II . In order to overcome the problem of sample matrix effects on the fluorogenic reagent, the method of standard AI conc (ng/mL) Figure 4 . A, determination oral in a diluted hemodialysis solution; B, calibration curve; C, the same hemodialysis solution as in A, spiked with 8 ng/mL aluminum.
additions was applied. A1 levels in hemodialysis solutions were determined by means of extrapolation. Various amounts of standard aluminum solutions (10 pg/mL), which corresponded to 0, 4, 8, and 16 ng/mL, were added to 1-mL aliquots of dialysis solution samples. Resulting emission values were plotted against the concentration of added Al, and the original AI concentration was determined by extrapolating the least-squares straight line to zero emission. The assay results for a sample of solution SIF-BP466/A and the corresponding calibration curve are reported in Figures 4A and 4B . The difference between the x-axis intercepts is 0.72 ng/mL, which, when multiplied by 12.5 (dilution coeffi- cient, as reported in Experimental), gives a final Al concentration in the sample equal to 9 ng/mL. The results of assays are summarized in Table II .
Recovery studies were performed in order to verify the accuracy of the proposed spectrofluorimetric procedure. The extrapolation method was applied to the same solution, which was spiked with a known amount of A1 that corresponded to 8 ng/mL. The difference between the x-axis intercepts was used to determine Al recovery, and a mean recovery value of 99% ( Figure 4C ) was obtained. Interference from iron ions present at trace levels in dialysis solutions was eliminated by adding 0.01M phenantroline solution (see Experimental). Other ions, such as Ba 2 § Ca 2 § and Mg ~ § were studied; it was found that they have little influence on the accuracy of AI level determination in dialysis fluids, especially if the extrapolation method is used. 
Conclusions
The proposed spectrofluorimetric method is simple and reliable. It allows for the direct determination of Al amounts in hemodialysis solutions with good precision and accuracy and employs small sample volumes.
In this work, only hemofiltration solutions were analyzed, excluding concentrated hemodialysis solutions. The latter, even if Al-free when packaged, can be contaminated with imperfectly deionized water during dilution (especially in developing countries).
All analyzed solutions contained less than 10 ng/mL of Al (Table II) , which is the highest allowable concentration for hemofiltration solutions following the Farmacopea Ufficiale Italiana (7) and the European Pharmacopeia (8) .
The proposed spectrofluorimetric method, based on the complexation of the Al with MR19, is thus suitable for the determination of the Al content in hemodialysis solutions. Its fundamental advantages are satisfactory sensitivity even when using small sample volumes, high stability of the A1-MR19 complex, low reagent toxicity, and good reproducibility.
When compared with previously developed methods (23, 24) , the proposed method is more precise and more accurate. In terms of sensitivity, it is superior to the procedure based on the Pontachrome Blue-Black reagent and similar to the procedure based on Morin reagent.
Furthermore, in a future development of this research, the method could be suitable because of its selectivity and sensitivity, after slight experimental modifications, for the assay of aluminum levels in human blood and other biological fluids and tissues (such as brain samples).
